Company Performance Metrics
- Sunjay Kaushal: Founder & Chief Medical Officer
- Vinny Jindal: President & CEOPast Role: Stockr, Chief Executive Officer, Co-Founder, Board Member
Secretome Therapeutics is a clinical-stage biotechnology company developing therapies derived from neonatal cardiac progenitor cells (nCPCs) for cardiovascular and inflammatory diseases. Its research focuses on regenerative and immunomodulatory approaches for conditions such as heart failure with preserved ejection fraction (HFpEF), dilated
cardiomyopathy (DCM), and Duchenne-associated cardiomyopathy. The company’s lead therapeutic candidate, STM-01, is being evaluated in clinical trials, while additional programs such as STM-21 are in preclinical development for inflammatory and tissue repair applications. Secretome Therapeutics uses neonatal cardiac tissue obtained during medically necessary surgeries to develop cell-based and secretome-based therapies intended to support tissue repair and reduce inflammation. The company’s platform is designed to produce scalable and consistent therapies by using neonatal-derived cells that demonstrate lower variability compared to adult-derived stem cells.